BPC-157 is not FDA approved. That is the most important sentence on this page. Despite widespread online discussion and marketing claims from various sellers, BPC-157 has not been authorized by the FDA as a drug product for any use.
What "FDA approved" actually means
An FDA-approved drug has gone through a New Drug Application (NDA) or Biologics License Application (BLA), including controlled clinical trials demonstrating safety and efficacy, with the agency reviewing safety, manufacturing quality, and labeling. The process is rigorous by design — it ensures that what's on the label matches what's in the vial, and that the benefit-risk profile is understood.
BPC-157 has not entered this pathway in the United States. No sponsor has filed an NDA or BLA for BPC-157. The FDA has not reviewed clinical trial data for a BPC-157 drug application because no such application exists.
Compounding is a separate pathway
Some peptides have historically been used in compounded preparations under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Compounding is not the same as FDA approval — it is a different regulatory framework with different rules.
Under 503A, traditional compounding pharmacies can prepare patient-specific medications using ingredients from an FDA-maintained list called the 503A bulks list. BPC-157 is not currently on that list. The FDA has raised safety concerns regarding certain compounded peptide substances and has formally scheduled a PCAC discussion of BPC-157-related substances for July 23, 2026.
Current U.S. status — in plain language
- Not FDA approved as a drug product.
- Not on the 503A bulks list for compounding.
- Subject to ongoing FDA review — a PCAC discussion is scheduled for July 23, 2026.
- Not offered for sale, prescription, or dispensing through BPC157.now.
What about products sold online?
Many products are sold online labeled as "research chemicals," "not for human use," or as imported substances from non-U.S. sources. These labels do not create legal exemptions from FDA oversight of drug products — they are marketing hedges, not regulatory safe harbors.
The FDA has limited enforcement resources and has historically prioritized large-scale, egregious violations. The existence of online sales does not mean those sales are legal — it means enforcement hasn't reached them yet, or they exist in a gray area the agency is still actively evaluating.
Why this matters for consumers
Products sold outside the FDA approval or compounding frameworks carry unknown quality risks. Without FDA oversight of manufacturing, there is no assurance of identity (is this actually BPC-157?), purity (what else is in it?), or potency (is the labeled amount accurate?). Independent testing of unregulated peptides has historically found significant quality problems.
The educational purpose of this site is to help readers track the formal process — including the July 2026 PCAC hearing — so they understand what any regulatory change actually means when it happens, rather than relying on social-media distortion.
